June 2023
Volume 64, Issue 8
Open Access
ARVO Annual Meeting Abstract  |   June 2023
Potential Therapeutic Effects of Wnt Signaling Pathway’s Role in Limbal Stem Cell Development Using Novel Small Molecule Wnt Mimic, FZD7L-ND
Author Affiliations & Notes
  • Christiana Han
    Jules Stein Eye Institute, University of California Los Angeles, Los Angeles, California, United States
  • Chi Zhang
    Jules Stein Eye Institute, University of California Los Angeles, Los Angeles, California, United States
  • Jie J Zheng
    Jules Stein Eye Institute, University of California Los Angeles, Los Angeles, California, United States
  • Footnotes
    Commercial Relationships   Christiana Han None; Chi Zhang None; Jie Zheng None
  • Footnotes
    Support  National Eye Institute (R01EY021797, R01EY028557, and 5P30EY000331), California Institute for Regenerative Medicine (TR2-01768, BF1-01768) and an unrestricted grant from Research to Prevent Blindness.
Investigative Ophthalmology & Visual Science June 2023, Vol.64, 3166. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Christiana Han, Chi Zhang, Jie J Zheng; Potential Therapeutic Effects of Wnt Signaling Pathway’s Role in Limbal Stem Cell Development Using Novel Small Molecule Wnt Mimic, FZD7L-ND. Invest. Ophthalmol. Vis. Sci. 2023;64(8):3166.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : Ex-vivo expanded limbal stem cells(LSCs) transplantation face challenges in replicating an artificial niche that excludes the use of xenobiotic free products. A new small molecule Wnt mimic, FZD7L-ND, which specifically targets Wnt receptor FZD7, was hypothesized to have both activating effect on the Wnt pathway and improvement of LSCs culture in-vivo using experimental models of luciferase reporter assay and cultured LSC's.

Methods : The ability of FZD7-ND on inducing Wnt signaling was evaluated by TOP-Flash assay. HEK 293 cells were treated with FZD7L-ND(1-20 uM) and varying concentrations of Wnt3a(2-10.7 nM). Cell viability(fluorescence) and Wnt pathway activity(luciferase) was measured using Microplate Reader. The Wnt pathway activity was expressed as ratio of fluorescence to luciferase. Shapiro-Wilk was used to determine normal distribution. Ordinary one-way ANOVA was used to determine statistical significance. Standard deviation shown as error bars. P-values 0.05 ≤ were considered statistically significant. LSC’s were isolated and cultured from fresh tissue. At nine days, the wells were harvested, counted, and stained for K12, K14, and p63 bright cells. In separate wells, the colonies were stained with 0.5% rhodamine B to determine colony forming efficiency.

Results : TOPFlash results show significant activation of the Wnt pathway(p value < 0.05), with a significant value around 10 uM of FZD7L-ND. At higher concentrations of Wnt3a(6.7 and 10.7 nM) there is a large exponential increase in the activation[ZJJ1] . In vivo, 10 uM FZD7L-ND has 1.74 fold change improvement in cell proliferation and 2.12 improvement in %p63 bright cells.

Conclusions : The novel FZD7L-ND has very significant activation of the Wnt pathway in reporter assays. Compared to previous small molecule, FZD7L-ND displays greater selectivity, denoted by the lower concentration needed in the luciferase assay. Greater selectivity helps to create a targeted response while also decreasing concentration required for treatment. While more testing is needed to determine in vivo significance, preliminary tests show that FZD7L-ND influences limbal stem cell proliferation and a key stem cell marker, %p63. FZD7L-ND can potentially have a crucial role in advancing limbal stem cell deficiency therapeutics by helping to maintain and proliferate LSCs in vivo via Wnt pathway activation.

This abstract was presented at the 2023 ARVO Annual Meeting, held in New Orleans, LA, April 23-27, 2023.

 

 

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×